This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Acute pericarditis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Acute pericarditis is the inflammation of the pericardium.

At least one in four patients are at risk of recurrence.

Principles of management:

  • non-steroidal anti-inflammatory drugs (NSAIDs) remain the cornerstone of treatment
  • addition of 3 months of colchicine can more than halve the risk of recurrence (number needed to treat = four) (1)
    • evidence shows that in patients with first attack of pericarditis associated with myocardial involvement, colchicine was safe and efficacious for the reduction of recurrences (2)
  • low-dose steroids can be helpful second-line agents for managing recurrences as adjuncts to NSAIDs and colchicine but should not be used as first-line agents

Reference:

  • Ismail TF. Acute pericarditis: Update on diagnosis and management. Clin Med (Lond). 2020 Jan;20(1):48-51.
  • Collini V, De Martino M, Andreis A, et al Efficacy and safety of colchicine for the treatment of myopericarditis Heart Published Online First: 18 January 2024. doi: 10.1136/heartjnl-2023-323484

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.